Incyte (INCY) PT Raised to $98 at Argus on Jakafi Sales and Takeover Potential

September 26, 2016 7:21 AM EDT
Get Alerts INCY Hot Sheet
Price: $102.02 +2.09%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade INCY Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Argus reiterated a Buy rating and raised its price target on Incyte (NASDAQ: INCY) to $98.00 (from $92.00) based on higher-than-expected 2Q16 sales and EPS and increased company guidance for Jakafi sales in 2016.

In addition, they believe Incyte could be a takeover candidate given the recent uptick in healthcare M&A and selloff in biotech stocks, perhaps from Gilead (NASDAQ: GILD) who may want to boost its oncology pipeline.

The firm is raising 2016 EPS estimate to $0.45 from $0.32. They are also raising 2017 estimate to $1.33 from $1.31. Additionally, they are maintaining their revenue forecast at $1.0 billion for 2016 and raising their forecast to $1.4 billion from $1.3 billion for 2017.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $88.98 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Rumors

Related Entities


Add Your Comment